OncoSec Medical Inc (ONCSQ)

[hschlauch]

One important point on the patient population for the registration trial - refractory patients include partial responders. Thus far, the highest complete response rates in metastatic melanoma observed and reported have been with combination Yervoy and Opdivo (22%) for BRAF wild-type. Partial responses are around 39%, for a total 61% BORR. Therefore, we are looking at a patient pool that is relatively large due to the fact that the highest treatment bar (Yervoy plus Opdivo) is unable to produce complete responses or any response in approximately 78% of metastatic melanoma patients with BRAF wild-type. This is a smart move and a major unmet need.